Belgium
Convert Pharmaceuticals, founded in 2018 and headquartered in Belgium, is a clinical-stage biotech company focused on overcoming cancer treatment resistance. Their slogan, "Overcoming cancer treatment resistance with hypoxia-activated prodrugs," highlights their commitment to innovative healthcare solutions. The company's proprietary pipeline features biomarker-enabled hypoxia-activated prodrugs designed to treat resistant solid tumors, marking a significant advancement in the biotechnology and pharmaceutical industries.
Since its inception, Convert Pharmaceuticals has demonstrated its growth potential with a notable Series A investment of €13.60M secured on 28 February 2018. This investment round drew significant interest from a consortium of investors, including Noshaq, Droia Ventures, Walloon, Eurostars, and Spinventure. Their backing underscores confidence in Convert Pharmaceuticals's innovative approach and potential to address key challenges in cancer treatment.
